Inside Sedivention’s One‑Time Cryoablation Therapy for Obesity

Obesity treatments today often fall into two extremes: invasive bariatric surgery or long‑term medications such as GLP‑1 drugs. A German medtech startup, Sedivention, is developing a different approach—an outpatient procedure designed to reduce hunger signals with a single minimally invasive treatment.

The company’s technology uses a cryo‑balloon catheter to temporarily freeze specific branches of the vagus nerve in the stomach. By interrupting these hunger‑related signals, the therapy aims to help patients feel less hungry and potentially achieve sustained weight loss without implants, surgery, or lifelong medication.

What Sedivention’s therapy is

Sedivention is building a device‑based obesity treatment centered on a cryoablation catheter sometimes referred to as the “Blizzard Catheter.” The system is designed for a one‑time outpatient procedure targeting the gastric trunks—branches of the vagus nerve involved in hunger signaling.

Instead of removing stomach tissue or implanting hardware, the technology applies controlled cold therapy to these nerves. The goal is to reduce the sensation of hunger by disrupting neural signals that travel between the stomach and brain.

If successful, the company hopes the approach could deliver a long‑lasting reduction in appetite after a single intervention. However, the treatment remains under development and has not yet been proven in large human studies.

How the balloon‑catheter cryoablation procedure works

The procedure is designed to resemble a standard gastroscopy, meaning the catheter is inserted through the mouth and guided into the stomach using an endoscopic approach rather than surgical incisions.

Once positioned:

• A balloon catheter is inflated inside the stomach.
• The device delivers cryotherapy (extreme cold) to the gastric branches of the vagus nerve.
• The cold exposure causes cryoablation—disrupting the nerve signals associated with hunger.
• The balloon is deflated and the catheter is removed.

The entire procedure is intended to take roughly 20 minutes and be performed in an outpatient setting.

Why targeting the vagus nerve may reduce hunger

The vagus nerve is a key communication pathway between the digestive system and the brain. Signals traveling through this nerve help regulate appetite, satiety, and digestive activity.

By disrupting specific gastric branches of this nerve, Sedivention aims to interfere with hunger signaling at its source. Instead of blocking appetite chemically with drugs, the therapy attempts to modify the neural pathway responsible for transmitting hunger signals.

This concept is not entirely new—other obesity technologies have targeted vagus nerve signaling—but many of those approaches rely on implanted stimulators or devices. Sedivention’s strategy differs by using a single cryoablation procedure without leaving hardware inside the body.

Why it’s being explored as an alternative to surgery or drugs

Current obesity interventions often involve significant trade‑offs:

• Bariatric surgery can produce substantial weight loss but requires invasive procedures and permanent anatomical changes.
• Weight‑loss medications may require ongoing use and can be expensive or cause side effects.

Sedivention’s approach attempts to sit between these options. The proposed advantages include:

• A one‑time procedure rather than chronic therapy
• No surgical incisions or stomach removal
• No implanted hardware
• Potential long‑lasting appetite reduction

Because of these features, the technology is being positioned as a possible device‑based alternative for people who need more help than lifestyle changes but want to avoid major surgery or lifelong medication.

The €2.9M seed funding and what it will support

In 2026, Sedivention raised €2.9 million in seed funding led by bmp Ventures alongside the IBG funds. Additional investors include High‑Tech Gründerfonds (HTGF), Cambridge Ventures, superangels, and the strategic investment arm of a global medtech company.

The capital is intended to support several key milestones:

• Completing product development of the cryo‑balloon catheter
• Generating early clinical evidence
• Conducting a first‑in‑human study
• Preparing for regulatory approval and future commercialization

These steps are necessary before the device can be widely used in clinical practice.

Current development stage

Despite growing investor interest, the therapy is still in early development. Reports describe the device as being in preclinical or early clinical preparation stages, meaning its long‑term effectiveness and safety still need to be demonstrated in human trials.

If clinical studies confirm that targeted vagus nerve cryoablation can reliably reduce hunger and support weight loss, the approach could represent a new category of minimally invasive obesity treatment. Until then, it remains a promising but experimental technology.